Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02596698 · ClinicalTrials.gov registry record
Mitochondrial Dysfunction, Inflammation, and White Matter Integrity in Youth With Mood Disorders
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 54
- Enrollment target
NCT02596698: Completed study, sponsored by University of Minnesota.
NCT02596698 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02596698 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
This study consists of three separate appointments including a clinical assessment (interview and questionnaires), a blood draw, a social stress test, and a brain MRI.
Primary Outcome
Blood samples will be analysed for mitochondrial dysfunction and resulting oxidative damage to lipids, and protein and messenger ribonucleic acid levels of inflammatory cytokines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2015-10-31 |
| Est. Completion | 2018-03-31 |
What the finished NCT02596698 record still lists
NCT02596698 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02596698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02596698 about?
NCT02596698 is a clinical study titled "Mitochondrial Dysfunction, Inflammation, and White Matter Integrity in Youth With Mood Disorders". This study consists of three separate appointments including a clinical assessment (interview and questionnaires), a blood draw, a social stress test, and a brain MRI.
What is the current status of trial NCT02596698?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2015-10-31. Estimated completion is 2018-03-31.
Who is sponsoring clinical trial NCT02596698?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI